Revolutionising Oral Drug Delivery

The challenge of oral drug delivery is ensuring that therapeutics survive the harsh GI conditions while achieving efficient intestinal uptake. NovoArc’s platform addresses this by engineering protective lipid-based carriers that stabilize APIs and enhance absorption. This technology enables oral delivery for medications like antibiotics, insulin, and mRNA vaccines.

Nature-Inspired Technology
NovoArc takes inspiration from nature. Microorganisms in hot sulfur springs endure extreme temperatures and acidity due to specialized lipids in their cell membranes. NovoArc uses these lipids to protect APIs in the GI tract and during storage. This strategy enhances drug stability, enabling oral administration and improving patient compliance.

NovoArc has the expertise and IP to chemically modify lipids based on customer needs. By adjusting lipid properties, the company enhances drug encapsulation or functionalises lipids with ligands for targeted drug delivery.

NovoArc collaborates with pharma partners to accelerate drug development. The company supports partners from formulation to market-ready products, providing specialty lipids to drive innovation and bring new therapies to patients.

Positioned for Success
Founded by David Wurm, Julian Quehenberger, and Oliver Spadiut, and supported by an expert advisory board, ­NovoArc is a leader in oral drug delivery. With recent funding from AWS and FFG, NovoArc is advancing its technology and expanding its platform. In collaboration with pharmaceutical partners, NovoArc aims to bring its first products to clinical trials, paving the way for a new generation of orally administered pharmaceuticals.

NovoArc is also a proud member of BIOTECH AUSTRIA (www.biotechaustria.org), benefiting from its strong industry network, advocacy, and collaboration opportunities within the Austrian and European biotech landscape. BIOTECH AUSTRIA fosters innovation and supports companies like NovoArc in bringing groundbreaking technologies to market.

This article war originally published in European Biotechnology Magazine Spring 2025.